Notably, CD24-targeted vesicles demonstrated superior tumor suppression compared to non-targeted formulations, which can be attributed to enhanced tumor accumulation mediated by CD24 antibody-directed targeting (Fig. 5CD). This evidence concerns the gene CD24 and neoplasm.